REG - Eden Research plc - Director/PDMR Shareholding

Eden ResearchAnnouncement

28/06/2019 07:05

RNS Number : 7385D
Eden Research plc
28 June 2019
 


 
 
28 June 2019
 
Eden Research plc
 
("Eden" or "Company)
 
 
Director/PDMR Shareholding
 
Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, announces that Lykele van der Broek, Chairman, has purchased 358,500 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at an average price of 10.94 pence per Ordinary Share.
 
Following the transaction outlined above, Mr van der Broek is interested in 358,500 Ordinary Shares representing 0.17 per cent. of the Company's issued share capital. 
 
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details of the PDMR dealing set out above.
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 


Mr Lykele van der Broek




2
 


Reason for the notification
 




a)
 


Position/status
 
 


Chairman




b)
 


Initial notification /Amendment
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 


Eden Research plc
 




b)
 


LEI
 
 


213800ZWTYTVQQSM3J85




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary shares of 1 pence each in the Company ("Ordinary Shares")
 
GB0001646941
 




b)
 


Nature of the transaction
 


Purchase of Ordinary Shares
 
 




 
 
 
c)
 


 
 
 
Price(s) and volume(s)
 
 


 
 



Price(s) - pence per share


Volume(s) - Ordinary Shares




 
10.5
10.47
10.75
10.737
11.41


 
40,000
40,000
40,000
100,000
138,500



 
 




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


 
 
358,500 Ordinary Shares
 
10.94 pence per share




e)
 


Date of the transaction
 


27/6/2019




f)
 


Place of the transaction
 
 


LSE, AIM Market (XLON)
 



 
For further information contact:



Eden Research plc


www.edenresearch.com




Sean Smith
Alex Abrey


01285 359 555














Shore Capital (Nomad)


020 7408 4090




Stephane Auton / Patrick Castle


















Powerscourt (Financial PR)


020 7250 1446




Nick Dibden
Jana Tsiligiannis


eden@powerscourt-group.com



 
 
Notes:
 
Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer products industries.
 
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.
 
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
 
Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
 
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements. 
 
In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company.  To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.
 
3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania, Portugal and Macedonia.
 
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
 
For more information about Eden, please visit: www.edenresearch.com.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHSELFUWFUSELM